Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients

NCT00524277 is registered in ClinicalTrials.gov with San Antonio Military Medical Center as lead sponsor.

NCT NCT00524277
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00524277 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients
Lead sponsor
San Antonio Military Medical Center
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2007
Completion date
March 31, 2017
Enrollment
456 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer